Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (May 2026)
19 slides from Inmed Pharmaceuticals's investor presentation, May 2026
Slide 1: INM-901 Alzheimer's Disease Acquisition Opportunity
INM-901 Alzheimer’s Disease Acquisition Opportunity May 2026 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is the most common form of dementia • 7.2M Americans affected that impacts the part of the brain that controls • 1 in 9 people age 65+ (11%) though
Slide 4: The Role of Neuroinflammation in Alzheimer's Disease
Evolving Perspective in the AD Community: The Role of Neuroinflammation in Alzheimer’s Disease Historical View OLD VIEW NEW VIEW • Aβ (amyloid-beta) and tau considered the primary causes of AD New Perspective • Aβ and tau are now viewed as part of a more complex disease process Aβ & Tau Aβ & Tau • A
Slide 5: The Key Players in Neuroinflammation: Microglia and Astrocytes
The Key Players in Neuroinflammation: Microglia and Astrocytes Microglia Astrocytes (The Sentinels) (The Support System) Protective Protective Responsible for neuroinflammation Releases anti-inflammatory resolution, phagocytosis of debris, molecules (TGF-β) and TGF-β GDNF and anti-inflammatory actio
Slide 6: Role of CB1/CB2 Receptors in Targeting Microglia and Astrocytes
Role of CB1/CB2 Receptors in Targeting Microglia and Astrocytes Role of CB2 Receptors in Neuroinflammation – Anti-inflammatory While INM-901 is primarily a • Immune Regulation: Highly expressed on microglia and astrocytes during CB2 agonist, both CB1 and inflammation, CB2 receptors are upregulated i
Slide 7: INM-901 Mechanism of Action on Neuroinflammation
INM-901 Mechanism of Action on Neuroinflammation nlrp3 Inflammasome Rationale: Since inflammation is a core driver NEURON of AD, modulating inflammatory immune response is a promising therapeutic strategy. ASTROCYTE MICROGLIA INM-901 INM-901 data, via the CB2 pathway, demonstrates down-regulation of
Slide 8: INM-901 Demonstrates Positive Impacts on AD Pathologies
INM-901 Demonstrates Positive Impacts on AD Pathologies Multiple pro-inflammatory and neurodegenerative proteins are elevated in AD; INM-901 demonstrated meaningful decreases in these proteins. AD INM-901 Astrocyte GFAP TNF-⍺ IFNy IL-1β Microglia IL-6 CB2 NfL
Slide 9: Proof of Concept in Alzheimer's Using 5xFAD Mouse Model
INM-901 Proof of Concept in Alzheimer’s Using 5xFAD Mouse Model LONG TREATMENT DURATION AND ADVANCED DISEASE STAGE + + + 9-month-old male mice 2-month-old male mice were injected twice-weekly for 7 months This study evaluates INM-901 in the 5xFAD (amyloidosis) mouse model, using a long treatment dur
Slide 10: Positive Trends in Cognitive Function, Anxiety-Related Behavior and Sensory Responsiveness
INM-901 Demonstrates Positive Trends Across all Tested Parameters in Cognitive Function, Anxiety-Related Behavior and Sensory Responsiveness 5xFAD mice spent more time in the center zone or open arms, suggesting reduced anxiety-like behavior. INM-901 treatment restored typical anxiety-like behavior
Slide 11: Strong Neuroinflammatory Modulation in 5xFAD Mouse Model
INM-901 Demonstrates Strong Neuroinflammatory Modulation in 5xFAD Mouse Model Plasma Inflammatory Biomarkers 5xFAD transgenic mice exhibited significantly elevated levels of these markers compared to wild-type mice. Treatment with INM-901 at 15 or 30 mg/kg resulted in a significant reduction in thes
Slide 12: Reduces Inflammatory Markers in Brain Tissues of Ex Vivo LPS Model
INM-901 Reduces Inflammatory Markers in the Brain Tissues of Ex Vivo LPS Model • Pro-inflammatory markers increased following LPS exposure • Cytokines/Chemokine in the INM-901 treated groups showed a reduction in inflammation compared to the LPS group • INM-901 can exert a direct anti- inflammatory
Slide 13: Anti-inflammatory Effects in 3D Human Brain Organoid Model
INM-901 Anti-inflammatory Effects in 3D Human Brain Organoid Model HUMAN ORGANOID DATA CONSISTENT WITH IN VIVO AND EX VIVO RESULTS INM-901 Effects in Brain Organoid Model • Significant reduction in neuroinflammation in Stem Pharm’s LPS-induced and Alzheimer’s disease models • A dose-dependent reduct
Slide 14: Summary: INM-901 Impact on Alzheimer's Pathology
Summary: INM-901 Impact on Alzheimer’s Pathology Robust Bioavailability Behavioral Improvements Anti-Inflammatory Action – 5xFAD Oral formulation achieved Improved behavior and Significantly reduced anticipated therapeutic levels cognitive function in inflammatory biomarkers IFNγ, of systemic exposu
Slide 15: Pipeline Next Steps
Pipeline Next Steps Research & Development InMed activities: • Pre-IND meeting with the U.S. Food and Drug Administration planned for summer 2026 • Top-line clinical plan developed On hold pending acquisition: • Completion of remaining IND-enabling pharmacology and toxicology studies • Finalization
Slide 16: Additional Information available under CDA
Additional Information available under CDA • Neurological assessment in dogs • No negative impact on general attitude, behavior, motor function. • PK studies in mice, rats and dog • Dose Ranging Studies in rats and dogs • DMPK studies • CMC scale-up activities • Regulatory planning activities toward
Slide 17: Key Patent Summary
Key Patent Summary All key patents in place to support the INM-901 program Subject Matter Scope Ownership/ Filing Status / Patent Reference Earliest Potential/ Jurisdictions - Origin Filing Date Number – Status Patent Expiry2 Patent Nos. Cannabinoid analogs and Composition, Assigned to InMed(CA) PCT
Slide 18: Current Pharmaceutical R&D Team
Current Pharmaceutical R&D Team Technical and scientific expertise may be available post-acquisition Eric Hsu, PhD Charles Marlowe, PhD Jim Kealy, PhD Michael Woudenberg, PEng Sapna Padania SVP, Preclinical R&D VP, Chemistry VP, Synthetic Biology Chief Operating Officer Scientist III 20+ years of en
Slide 19: Thank you!
Thank you! Forward Inquiries to Colin Clancy Cclancy@inmedpharma.com +1-778-855-2408 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (May 2026) on 6ix